Cat. No.: HY-17536

Selinexor

(Synonyms: KPT-330)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Selinexor (KPT-330) is an analog of KPT-185 (HY-15611). Selinexor is an orally active, selective CRM1 inhibitor that inhibits tumor growth by inducing PANoptosis.

For research use only. We do not sell to patients.

Purity: 99.83%
CAS No.: 1393477-72-9
Formula: C₁₇H₁₁F₆N₇O
Molecular Weight:443.31

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Selinexor Chemical Structure

CAS No.: 1393477-72-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Selinexor (KPT-330) is an analog of KPT-185 (HY-15611). Selinexor is an orally active, selective CRM1 inhibitor that inhibits tumor growth by inducing PANoptosis^[1]^[2]^[3].

IC₅₀ & Target

CRM1

Cellular Effect

Cell Line	Type	Value	Description	References
HEK-293T	IC₅₀	0.73 μM Compound: KPT-330	Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Cytotoxicity against HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38105606]
HeLa	IC₅₀	0.43 μM Compound: KPT-330	Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay	[PMID: 38105606]
HPBALL	IC₅₀	34 nM Compound: KPT-330	Antiproliferative activity against human HPBALL cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay Antiproliferative activity against human HPBALL cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay	[PMID: 38105606]
Jurkat	EC₅₀	17 nM Compound: 1; KPT-330	Cytotoxicity against human Jurkat cells incubated for 24 hrs by celltiter glo assay Cytotoxicity against human Jurkat cells incubated for 24 hrs by celltiter glo assay	[PMID: 39005064]
Jurkat	IC₅₀	34 nM Compound: KPT-330	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay	[PMID: 38105606]
KOPTK1	IC₅₀	34 nM Compound: KPT-330	Antiproliferative activity against human KOPT-K1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay Antiproliferative activity against human KOPT-K1 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay	[PMID: 38105606]
MOLT-4	IC₅₀	34 nM Compound: KPT-330	Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay Antiproliferative activity against human MOLT-4 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter Glo assay	[PMID: 38105606]
NSCLC	IC₅₀	25 nM Compound: 2; KPT-330	Antitumor activity against human NSCLC cells Antitumor activity against human NSCLC cells	[PMID: 34669417]

In Vitro

As the clinical candidate analog of KPT-185, KPT-330 exhibits similar effects on the viability of T-ALL cells and elicits rapid apoptotic response. KPT-330 also reduces cell growth in MOLT-4, Jurkat, HBP-ALL, KOPTK-1, SKW-3, and DND-41 cell lines, with IC₅₀ values of 34-203 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Selinexor (KPT-330) dramatically suppresses the growth of T-ALL cells (MOLT-4) and AML cells (MV4–11) in vivo, with little toxicity to normal haematopoietic cells^[1].
In SCID mice with diffuse human MM bone lesions, KPT-330 inhibits MM-induced bone lysis and prolongs survival. Moreover, KPT-330 directly impairs osteoclastogenesis and bone resorption by blocking RANKL-induced NF-κB and NFATc1, with minimal impact on osteoblasts and BMSCs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1393477-72-9
Appearance Solid
Molecular Weight 443.31
Formula C₁₇H₁₁F₆N₇O
Color White to light yellow
SMILES

O=C(NNC1=NC=CN=C1)/C=C\N2N=C(C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)N=C2
Synonyms

KPT-330
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (13)

All IPIHCWBFlow CytometryApoptosis Analysis

Sort by:

Journal Impact Factor

Cancer Lett

GPI inactivation mediates pentose phosphate pathway flux switch-on inducing temozolomide resistance in glioma stem cell. [Abstract]

2026 May 1:645:218384. PMID: 41763452
Int J Biol Sci

DBF4 Dependent Kinase Inhibition Suppresses Hepatocellular Carcinoma Progression and Potentiates Anti-Programmed Cell Death-1 Therapy. [Abstract]

2023 Jul 3;19(11):3412-3427. PMID: 37497004

Selinexor purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2023 Jul 3;19(11):3412-3427. [Abstract]

HCCLM3 cells were treated with or without TNF-α and Selinexor (1 mM, 72 hours) followed by STAT3 co-immunoprecipitation assay.
J Exp Med

TRIM24 facilitates antiviral immunity through mediating K63-linked TRAF3 ubiquitination. [Abstract]

2020 Jul 6;217(7):e20192083. PMID: 32324863
Apoptosis

The role of KPNA3 in multiple myeloma: implications for targeting nuclear import. [Abstract]

2026 Mar 11;31(3):98. PMID: 41813919
Leukemia

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. [Abstract]

2023 Jun;37(6):1336-1348. PMID: 36977823

Selinexor purchased from MedChemExpress. Usage Cited in: Leukemia. 2023 Jun;37(6):1336-1348. [Abstract]

Percent apoptotic cells following KO of mtNPM1 and treatment with Selinexor (KPT-330, 30-1000 nM) at the indicated concentrations for 48 hours.
Cell Rep

Extracellular matrix stiffness drives post-mitotic nuclear pore complex assembly to promote neuroblastoma pathogenesis. [Abstract]

2026 Jan 22;45(2):116858. PMID: 41575851
J Ethnopharmacol

Si-Wu-Tang attenuates hepatocyte PANoptosis and M1 polarization of macrophages in non-alcoholic fatty liver disease by influencing the intercellular transfer of mtDNA. [Abstract]

2024 Jun 28:328:118057. PMID: 38518965
Biochem Pharmacol

LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma. [Abstract]

2025 Jul:237:116948. PMID: 40228640

Selinexor purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jul:237:116948. [Abstract]

From the above animal model, the tumors were isolated and examined by immunohistochemistry and quantified by ImageJ to detect cleaved caspase3 protein expression in CTR-KD and HCG11-KD tumors treated with Selinexor (10 mg/kg, twice per week) or PBS.

Selinexor purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jul:237:116948. [Abstract]

Western blotting of PARP, cleaved PARP and cleaved caspase 3 in CTR-KD and XPO1-KD ARD cells treated with Selinexor (0.25 μM, 12 h).

Selinexor purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Jul:237:116948. [Abstract]

Apoptosis rates of CTR-KD and XPO1-KD ARD cells treated with Selinexor (0.25 μM, 48 h).
Cells

Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [Abstract]

2026 Jun 11;15(12):1070. PMID: 42346097
Mol Oncol

Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]

2026 Jun 5. PMID: 42246237
iScience

CCT3-mediated regulation of XPO1/RB1 axis stability promotes cellular senescence and tumor progression in clear cell renal carcinoma. [Abstract]

2026 Jan 29;29(3):114840. PMID: 41732260
J Clin Lab Anal

Exportin 1 Inhibitor Combined With Venetoclax Induces Apoptosis in Myelodysplastic Syndrome by Mitochondria-Induced Apoptosis Pathway. [Abstract]

2026 Jun;40(12):e70229. PMID: 42007609
Hematology

XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia. [Abstract]

2026 Dec 31;31(1):2664314. PMID: 42026967

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (225.58 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2558 mL

11.2788 mL

22.5576 mL

5 mM

0.4512 mL

2.2558 mL

4.5115 mL

10 mM

0.2256 mL

1.1279 mL

2.2558 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (4.69 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (4.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Etchin J, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013 Apr;161(1):117-27. [Content Brief]

[2]. Tai YT, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014 Jan;28(1):155-65. [Content Brief]

[3]. Camilli S, et al. Nuclear Export Inhibitors Selinexor (KPT-330) and Eltanexor (KPT-8602) Provide a Novel Therapy to Reduce Tumor Growth by Induction of PANoptosis. Cell Biochem Biophys. 2023 Sep;81(3):421-426. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2558 mL	11.2788 mL	22.5576 mL	56.3939 mL
	5 mM	0.4512 mL	2.2558 mL	4.5115 mL	11.2788 mL
	10 mM	0.2256 mL	1.1279 mL	2.2558 mL	5.6394 mL
	15 mM	0.1504 mL	0.7519 mL	1.5038 mL	3.7596 mL
	20 mM	0.1128 mL	0.5639 mL	1.1279 mL	2.8197 mL
	25 mM	0.0902 mL	0.4512 mL	0.9023 mL	2.2558 mL
	30 mM	0.0752 mL	0.3760 mL	0.7519 mL	1.8798 mL
	40 mM	0.0564 mL	0.2820 mL	0.5639 mL	1.4098 mL
	50 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1279 mL
	60 mM	0.0376 mL	0.1880 mL	0.3760 mL	0.9399 mL
	80 mM	0.0282 mL	0.1410 mL	0.2820 mL	0.7049 mL
	100 mM	0.0226 mL	0.1128 mL	0.2256 mL	0.5639 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Selinexor

Anti-Infection Compound Library

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Targeted Therapy Drug Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Selinexor

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Selinexor

Anti-Infection Compound Library

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Targeted Therapy Drug Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Selinexor

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Selinexor Related Classifications

HY-17536 Related Classifications